Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Longevity Economy strategy - September 2021

  • 25 October 2021 (5 min read)

Businesses exposed to the longevity economy continue to see strong demand

  • Global markets experienced some volatility following all-time highs last month
  • Merck’s antiviral treatment for COVID-19 halved the risk of hospitalisation in its clinical trial
  • We initiated a position in a company providing on-board experiences to guests

What’s happening?

Macroeconomic concerns dominated investor sentiment in September. Uncertainty about potential contagion from the financial difficulties of China’s Evergrande, a potential shutdown of the US federal government, removal of fiscal stimulus, rising energy prices and continued supply chain disruption are just some of the issues unsettling equity markets. Not to mention the ever-present COVID-19 pandemic. But this obscures the positive progress being made on global vaccination programs for COVID-19 and emerging new treatments. For example, just after the period under review Merck announced that its oral antiviral treatment for COVID-19 halved the risk of hospitalisation in its clinical trial, showing yet again that, as a species, we continue to solve the complex problems we face with innovative solutions.

US Federal Reserve Chairman, Jerome Powell provided cautious remarks that higher inflation may persist longer than currently expected, which sent long-dated US government bond yields higher, but what must not be forgotten is that Powell also stated that economic growth continued to strengthen and inflation is still expected to moderate eventually.

In many of the conversations we have with leaders of businesses exposed to the longevity economy, they highlight that demand continues to strengthen, but there are challenges in recruiting labour and disruption to supply chains. Some have responded to this challenge by passing additional costs onto consumers, investing in greater automation and/or offering sign on bonuses to secure labour. Providing one-time bonuses and experiencing evolving supply chain issues would seem to support the notion that the issues are transitory.

Portfolio positioning and performance

The longevity economy strategy outperformed the broader equities market (MSCI All Country World) in September. While all four of our themes (wellness, silver spending, senior care and treatment) experienced weakness, it was less than the weakness experienced by global markets, principally due to the longevity economy’s lack of exposure to traditional technology companies.

Silver spending is a key theme for the longevity economy because consumption patterns are expected to change as populations age and the retired population increases. What is important to remember is a person reaching age 65 today is generally in better physical condition that a person reaching age 65 in the past due to improvements in medicine and nutrition. Therefore, we can expect older consumers to demand different goods and services than their forebears. This is perhaps most notable in the older population’s propensity to travel. The longevity economy strategy has long-maintained exposure to the cruise industry, which was hard hit by the COVID-19 pandemic but demand is rebounding, during September we increased our exposure to the theme by initiating a position in a company providing on-board experiences to guests. We also added exposure to Brunswick, which is a provider to the leisure boating industry.

We continued to pivot exposure away from value-orientated companies in the treatment theme where we perceive there are no clear catalysts to drive the market to re-evaluate the value of the stock.


Elevated macroeconomic concerns dominated investor sentiment in September, but we must not forget that Global markets hit all-time highs in August, so a pullback is natural. For many months economic data has often been contradictory, for example the US Federal Reserve has left open the possibility of tapering its stimulus program by year end suggesting confidence in US growth, but some jobs reports have indicated weaker hiring than expected, which could present problems for policymakers. Overall, we remain cautiously optimistic because continued innovation from companies, such as Merck, developing new treatments for COVID-19 continue to improve the standard of care and reduce the threat to life. Furthermore, global travel restrictions continue to ease, for example the US announced plans to ease travel restrictions from European countries in September, which should over time support a return to normality in global supply chains and economic activity.

Stepping back from macroeconomic considerations, we retain the view that high quality management teams, operating businesses with a sustainable competitive advantage and with the benefit of secular tailwinds are well-placed to navigate the current disruption. Despite the headwinds many businesses faced during the pandemic, the unshakeable conclusion on the outlook for the longevity economy is that the global population continues to age and this creates opportunities for companies that are positioned to benefit from long-term changes in consumption patterns that ageing populations will bring.

No assurance can be given that the Longevity Economy Strategy will be successful. Investors can lose some or all of their capital invested. The Longevity Economy Strategy is subject to risks including: Equity; Currency; Global Investments; Emerging markets; Investments in small capitalisation universe and Investment in specific asset classes.

Read the full article
Download article (227.86 KB)

Ageing and Lifestyle

Ageing and lifestyle describes the changing ways that people are living across the globe as life expectancies rise.

Find out more

Related Articles


Global Thematics strategy - February 2023

  • by David Shaw, Mark Hargraves
  • 21 February 2023 (5 min read)

Global Thematics strategy - January 2023

  • by David Shaw, Mark Hargraves
  • 15 February 2023 (5 min read)

Global Thematics strategy - July 2022

  • by Amanda O’Toole
  • 19 August 2022 (5 min read)

    Not for retail distribution

    This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs.

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. References to league tables and awards are not an indicator of future performance or places in league tables or awards and should not be construed as an endorsement of any AXA IM company or their products or services. Please refer to the websites of the sponsors/issuers for information regarding the criteria on which the awards/ratings are based. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

    The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site https://www.axa-im.com/en/registration-map, where a fund registration map is available. Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in an European Union country by notification to its authority of supervision in accordance with European passport rules. In particular units of the funds may not be offered, sold or delivered to U.S. Persons within the meaning of Regulation S of the U.S. Securities Act of 1933. The tax treatment relating to the holding, acquisition or disposal of shares or units in the fund depends on each investor’s tax status or treatment and may be subject to change. Any potential investor is strongly encouraged to seek advice from its own tax advisors.

    In the event of dissatisfaction with the products or services, you have the right to make a complaint either with the marketer or directly with the management company (more information on our complaints policy available in English here). You also have the right to take legal or extra-judicial action at any time if you reside in one of the countries of the European Union. The European online dispute resolution platform allows you to enter a complaint form (by clicking here) and informs you, depending on your jurisdiction, about your means of redress (by clicking here).

    Issued in the U.K. by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. 

    Are you an IFA or other Professional Investor ?

    Are you a financial advisor, institutional, or other professional investor?

    This section is for professional investors only. You need to confirm that you have the required investment knowledge and experience to view this content. This includes understanding the risks associated with investment products, and any other required qualifications according to the rules of your jurisdiction.